Mirae Asset Global Investments
VRDN icon

Mirae Asset Global Investments’s Viridian Therapeutics VRDN Stock Holding History

Mirae Asset Global Investments’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-28,822
Closed -$629K – 2521
2024
Q1 		$629K Buy
28,822
+1,135
+4% +$22K ﹤0.01% 1795
2023
Q4 		$603K Sell
27,687
-1,540
-5% -$24.3K ﹤0.01% 1880
2023
Q3 		$448K Buy
29,227
+4,412
+18% +$84.2K ﹤0.01% 1937
2023
Q2 		$592K Buy
24,815
+1,645
+7% +$42.2K ﹤0.01% 1864
2023
Q1 		$589K Buy
23,170
+6,702
+41% +$215K ﹤0.01% 1843
2022
Q4 		$481K Buy
16,468
+5,856
+55% +$135K ﹤0.01% 1917
2022
Q3 		$218K Buy
+10,612
New +$191K ﹤0.01% 2308

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Mirae Asset Global Investments's VRDN Position: Q2 2024 in Review

Mirae Asset Global Investments sold out of Viridian Therapeutics (VRDN) in Q2 2024, closing a stake of 28,822 shares — an estimated $629K sold.

Mirae Asset Global Investments first reported a position in VRDN in Q3 2022 and held it in 7 quarters. The position peaked at $629K in Q1 2024. 138 funds tracked by Wall St. Rank hold VRDN as of Q2 2024.

  • Mirae Asset Global Investments reported no remaining Viridian Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Mirae Asset Global Investments sold 28,822 Viridian Therapeutics shares in Q2 2024, an estimated $629K.
  • Mirae Asset Global Investments first reported a position in Viridian Therapeutics in Q3 2022 and held it in 7 quarters.
  • Mirae Asset Global Investments's Viridian Therapeutics position peaked at $629K in Q1 2024.
  • 138 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2024.

Based on Mirae Asset Global Investments's 13F filing for Q2 2024, filed 30 Jul 2024.